Jefferies is pleased to have served as Financial Advisor to SUN PHARMA on their $11.75 billion acquisition of Organon, a global leader in Women’s Health. Following the acquisition, Sun Pharma is poised to be among the top 25 global pharmaceutical companies, as well as have a top 3 position in global Women’s Health, and enter Biosimilars as a top 10 global player.The transaction represents the largest all-cash acquisition by an Indian company announced since 2006 and the largest Healthcare trans ...

Jefferies

Jefferies is pleased to have served as Exclusive Financial Advisor to Kelonia Therapeutics on its sale to Eli Lilly for up to $7.0 billion. Kelonia Therapeutics is a clinical-stage biotechnology company whose lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session.This transaction exemplifies Jefferies’ capabilities ...

Jefferies

Jefferies is pleased to have served as Sole Financial Advisor to Accent Equity, a leading Nordic mid-market private equity firm, in the closing of a multi asset continuation vehicle, Project Nexus, to extend its ownership of three high quality industrial and logistics portfolio companies: Tempcon, Nordic Grid Solutions, and ThorSvecon Group. Having had a record Q1 with $20B of closed / signed transaction volume, Jefferies Private Capital Advisory’s momentum has continued into Q2. In addition, as ...

Jefferies